Antibodies News and Research

RSS

Pfizer-BioNTech and Sinovac vaccines boost SARS-CoV-2 neutralizing responses

Researchers in the United States and Chile have provided preliminary evidence that individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – mount a robust neutralizing antibody response against the virus that can be significantly boosted by two doses of Sinovac Biotech’s CoronaVac vaccine or one dose of Pfizer-BioNTech’s BNT162b2 vaccine.

21 May 2021

Swiss study suggests very low prevalence of long COVID in pediatric population

Researchers from Switzerland recently analyzed long COVID symptoms in children and adolescents with a 6-month follow-up based on their SARS-CoV-2 serology. A longitudinal cohort analysis, the Ciao Corona study investigated SARS-CoV-2 seroprevalence and case clustering among ~2500 children from 55 primary and secondary schools in Zurich, Switzerland.

20 May 2021

Intranasal COVID-19 therapeutic shows promise in preclinical trials

Researchers from the US and Denmark recently described a novel therapeutic option that targets the SARS-CoV-2 ribonucleic acid (RNA) using locked nucleic acid antisense oligonucleotides (LNA ASOs). They identified an LNA ASO that binds to the 5’ leader sequence of SARS-CoV-2 ORF1a/b. This disrupts a highly conserved stem-loop structure with nanomolar efficacy and inhibits viral replication in host cells.

20 May 2021

Researchers speculate the low prevalence of COVID-19 in Japan

Protective immune memory--through B cells, which make antibodies, and/or T cells, which in the case of CD8+ T cells can kill virus-infected cells--can be induced by identical but also by related viruses.

20 May 2021

Does cross-immunity exist between SARS-CoV-2 B.1.1.28 and P.1 variants?

A team of researchers recently cross-tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies to assess their neutralization activity against different variants. The team recently released their findings as a preprint on the medRxiv* server.

20 May 2021

SARS-CoV-2 variant spread study in France shows B.1.351/V2 variant outgrowing B.1.1.7/V1 variant

A recent study by researchers in France has compared the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern. The team found a significant transmission advantage of V2 (from lineage B.1.351) over V1 (from lineage B.1.1.7). A pre-print version of the research paper is available on the medRxiv* server.

20 May 2021

A SARS-CoV-2 vaccine candidate based on B.1.351 spike trimer shows broad neutralizing capability

Researchers tested the vaccine candidate in mice with up to three doses and found it produces high levels of antibodies against both SARS-CoV-2 variants of concern and the original virus strain.

20 May 2021

Tokyo sees rapid rise of SARS-CoV-2 R.1 lineage

A new research paper posted to the preprint server medRxiv* reports the rise of a new lineage in Tokyo, Japan, bearing a combination of two biologically important mutations.

20 May 2021

Are COVID-19-related complications in children explained by abnormal immune responses?

A common theme in reports on COVID-19 around the world has been the large number of children who have not been infected or shown signs of disease. However, though the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes less acute infection in this age group, it is associated with a severe immune-mediated multisystemic illness called multisystem inflammatory syndrome in children (MIS-C).

20 May 2021

Early treatment may prevent clotting in COVID-19 vaccine-related thrombocytopenia

Now, a new report in the Journal of Thrombosis and Hemostasis reveals that timely diagnosis and treatment of this condition may prevent further morbidity and mortality, and enable the vaccine to be used widely with confidence.

20 May 2021

FDA reminds the public about the limitations of COVID-19 antibody

The following quote is attributed to Tim Stenzel, M.D., Ph.D., director of the Office of In Vitro Diagnostics and Radiological Health in the FDA's Center for Devices and Radiological Health.

20 May 2021

Monoclonal antibody bamlanivimab reduces hospitalization and death in moderate-to-severe COVID-19

Researchers at the University of Pittsburgh School of Medicine and the University of Pittsburgh Medical Center found that monoclonal antibodies, a COVID-19 treatment administered early after infection, reduce the risk of hospitalization and death by 60 percent in people at high risk of suffering complications from the condition.

20 May 2021

Protein-based vaccines against SARS-CoV-2 may provide advantages over mRNA-based vaccines

Researchers in the UK have developed a protein-based subunit vaccine directed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could serve as an alternative to the mRNA-based vaccines currently approved for protecting against coronavirus disease 2019 (COVID-19).

20 May 2021

Human monoclonal antibodies neutralize SARS-CoV-2 in an Fc-independent manner

Researchers from Israel recently isolated a set of SARS-CoV-2 neutralizing monoclonal antibodies from blood samples of patients with severe COVID-19. They were the first to show that transgenic K18-hACE2 mice infected with lethal doses of SARS-CoV-2 can be fully protected by administering antibodies even 3 days after infection

19 May 2021

Pfizer/BioNTech COVID-19 vaccine induces a stronger antibody response when given at an extended interval

Scientists have recently investigated the dynamics of immune responses in elderly people who have received two doses of the Pfizer/BioNTech COVID-19 vaccine.

19 May 2021

Spike antibodies after vaccination with Pfizer and Oxford vaccines

A preprint discusses the results of a study of antibody responses to the first and second dose of currently available SARS-CoV-2 vaccines, Pfizer and Oxford.

19 May 2021

The spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal antibodies

India’s surge in SARS-CoV-2 infections are linked to the new variants B.1.617 and B.1.618, with mutated spike proteins.

19 May 2021

Sequentia collaborated with Nextbiomics to obtain a novel immunization model against COVID-19

Sequentia Biotech and NextBiomics announced the filing of a patent application for a bacterial vaccine against the COVID-19 syndrome.

From Sequentia Biotech 19 May 2021

Presence of Anti-SARS-CoV-2 antibodies after 13 months of infection

A new study has been published on the medRxiv* preprint server which focuses on validating the serological assays using a large cohort of healthcare workers.

19 May 2021

Lengthy treatment with low-dose 6-mercaptopurine inhibits resistant triple-negative breast cancer cells

The cover for issue 7 of Oncotarget features Figure 5, "SUM149-MA cells surviving a 6-MP treatment are sensitive to chemotherapeutic drugs," published in "Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine" by Singh, et al. which reported that the authors have reported that a lengthy treatment with low-dose 6-mercaptopurine, a clinically useful anti-inflammatory drug, inhibits such resistant cells.

19 May 2021

Antibodies News and Research

Pfizer-BioNTech and Sinovac vaccines boost SARS-CoV-2 neutralizing responses

Swiss study suggests very low prevalence of long COVID in pediatric population

Intranasal COVID-19 therapeutic shows promise in preclinical trials

Researchers speculate the low prevalence of COVID-19 in Japan

Does cross-immunity exist between SARS-CoV-2 B.1.1.28 and P.1 variants?

SARS-CoV-2 variant spread study in France shows B.1.351/V2 variant outgrowing B.1.1.7/V1 variant

A SARS-CoV-2 vaccine candidate based on B.1.351 spike trimer shows broad neutralizing capability

Tokyo sees rapid rise of SARS-CoV-2 R.1 lineage

Are COVID-19-related complications in children explained by abnormal immune responses?

Early treatment may prevent clotting in COVID-19 vaccine-related thrombocytopenia

FDA reminds the public about the limitations of COVID-19 antibody

Monoclonal antibody bamlanivimab reduces hospitalization and death in moderate-to-severe COVID-19

Protein-based vaccines against SARS-CoV-2 may provide advantages over mRNA-based vaccines

Human monoclonal antibodies neutralize SARS-CoV-2 in an Fc-independent manner

Pfizer/BioNTech COVID-19 vaccine induces a stronger antibody response when given at an extended interval

Spike antibodies after vaccination with Pfizer and Oxford vaccines

The spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal antibodies

Sequentia collaborated with Nextbiomics to obtain a novel immunization model against COVID-19

Presence of Anti-SARS-CoV-2 antibodies after 13 months of infection

Lengthy treatment with low-dose 6-mercaptopurine inhibits resistant triple-negative breast cancer cells

From IHC to multiplexing: A practical guide for modern tissue analysis eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo